Implants on Mobile Health Unit
Adolescent Uptake of Implants on a Mobile Health Unit
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Brandon Hill, PhD
- Phone Number: 773.834.8509
- Email: bhill2@bsd.uchicago.edu
Study Contact Backup
- Name: Trevor Bak, BA
- Phone Number: 49965 7737021220
- Email: tbak@bsd.uchicago.edu
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- The University of Chicago Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Be biologically female
- Be seeking reproductive healthcare on a mobile health unit
- Be interested in receiving Nexplanon for birth control.
- Be between 14 and 19 years of age.
Exclusion Criteria:
- Be biologically male
- Be 13 and younger or 20 and older.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Nexplanon
This group is participants who choose to receive the nexplanon implant.
This group will only have one study interaction in the form of filling out a survey, at the time of implant.
|
This study is an exploratory study of user reasons for Nexplanon implant and removal, and NOT a study on the efficacy or safety of Nexplanon.
Nexplanon has already been FDA approved and its efficacy and safety studied.
|
|
Removal participants
This group is participants who choose to remove the nexplanon implant.
This group will only have one study interaction in the form of filling out a survey, at the time of removal.
Anyone with a Nexplanon implant can have the implant removed on the mobile health unit and become part of this group - removal participants do not need to be in the Nexplanon group.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Reasons for choosing Nexplanon
Time Frame: One time, immediately before receiving implant.
|
Information will be collected through a survey regarding why adolescents choose to receive Nexplanon.
|
One time, immediately before receiving implant.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Reasons for choosing to remove Nexplanon
Time Frame: One time, immediately before removing implant.
|
Information will be collected through a survey regarding why adolescents choose to remove Nexplanon.
|
One time, immediately before removing implant.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- IRB17-0233
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Supporting Information Type
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.